미리어드 제네틱스(MYGN) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 미리어드 제네틱스(MYGN)?

미리어드 제네틱스(MYGN) belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

Q: What is the market cap of MYGN?

The market cap of MYGN is approximately $514M, ranking 3,181 within its sector.

Q: What is the 52-week high and low for MYGN?

MYGN has recorded a 52-week high of $8.59 and a low of $3.53.

MYGN

Myriad Genetics Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$5.44

-0.17 ▼ -3.03%

🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)

$5.45

+0.00 +0.00%

미리어드 제네틱스(MYGN) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$514M

스몰캡

P/E

배당수익률

없음

52주 위치

38%

저점 +54% · 고점 -37%

애널리스트

보유

Fundamental health

vs. Diagnostics & Research· based on 3 axes

수익성

산출 불가 (적자)

성장

Top 61%

밸류에이션

Top 69%

재무 안정

Top 44%

Index ⓘ	RUT	P/E ⓘ	-	EPS (ttm) ⓘ	-4.32	Insider Own ⓘ	6.98%	Shs Outstand ⓘ	94.4M	Perf Week ⓘ	-8.11%
Market Cap ⓘ	0.51B	Forward P/E ⓘ	36	EPS next Y ⓘ	146.71%	Insider Trans ⓘ	2.12%	Shs Float ⓘ	87.9M	Perf Month ⓘ	0.18%
Enterprise Value ⓘ	0.60B	PEG ⓘ	0.55	EPS next Q ⓘ	-0.06	Inst Own ⓘ	92.29%	Short Float ⓘ	9.12%	Perf Quarter ⓘ	13.81%
Income ⓘ	-0.40B	P/S ⓘ	0.62	EPS this Y ⓘ	2.08%	Inst Trans ⓘ	-6.21%	Short Ratio ⓘ	4.98	Perf Half Y ⓘ	-7.33%
Sales ⓘ	0.83B	P/B ⓘ	1.52	EPS next 5Y ⓘ	65.44%	ROA ⓘ	-47.61%	Short Interest ⓘ	8.01M	Perf YTD ⓘ	-11.54%
Book/sh ⓘ	3.57	P/C ⓘ	4.13	EPS past 3/5Y ⓘ	-41.67% -8.03%	ROE ⓘ	-76.73%	52W High ⓘ	-36.67% ($8.59)	Perf Year ⓘ	22.25%
Cash/sh ⓘ	1.32	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	6.72% 5.24%	ROIC ⓘ	-73.81%	52W Low ⓘ	54.11% ($3.53)	Perf 3Y ⓘ	-74.99%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	-286.8%	Gross Margin ⓘ	66.14%	Volatility(W/M) ⓘ	4.31% 5.47%	Perf 5Y ⓘ	-82.38%
Dividend TTM ⓘ	-	EV/Sales ⓘ	0.72	Sales Y/Y TTM ⓘ	-0.28%	Oper. Margin ⓘ	-7.73%	ATR (14) ⓘ	0.3	Perf 10Y ⓘ	-83.26%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	2.19	EPS Q/Q ⓘ	-32981.82%	Profit Margin ⓘ	-48.24%	RSI (14) ⓘ	46.4	Recom ⓘ	2.89
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	2.4	Sales Q/Q ⓘ	2.3%	SMA20 ⓘ	-7.84% ($5.9)	Beta ⓘ	1.64	Target Price ⓘ	$6.14
Payout ⓘ	-	Debt/Eq ⓘ	0.63	Earnings ⓘ	2026/7/30	SMA50 ⓘ	9.81% ($4.95)	Rel Volume ⓘ	0.73	Prev Close ⓘ	$5.61
Employees ⓘ	2700	LT Debt/Eq ⓘ	0.61	EPS/Sales Surpr. ⓘ	-32.35% -1%	SMA200 ⓘ	-3.8% ($5.65)	Avg Volume(3M) ⓘ	1.61M	Price ⓘ	$5.44
IPO ⓘ	1995/10/6	Option/Short ⓘ	Yes/Yes			Trades ⓘ	10403	Volume ⓘ	1,172,148	Change ⓘ	-3.03%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $200M (YoY +2%) · 순이익 $-34M (YoY -34000%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Myriad Genetics Inc (MYGN) Investment Analysis

What kind of company is Myriad Genetics Inc?

미리어드 제네틱스(MYGN) 초고성장주

Healthcare · Diagnostics & Research

Healthcare Stocks

🧬 A US-based precision diagnostics company specializing in hereditary cancer testing and molecular diagnostics. As a pioneer in gene-based cancer diagnostic testing, it offers a molecular diagnostics portfolio that includes hereditary cancer risk testing (MyRisk), mental health drug response testing (GeneSight), and prenatal testing, and operates across the oncology, women's health, and mental health segments.

Learn more about Myriad Genetics Inc →

Market Cap

$0.5B

Approx. KRW 0.7 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank3181

Employees2,700people

IPO1995/10/06

Current Price$5.44 ≈ 7,453원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-2

7월 30일 (목) · 장 마감 후

예상 매출 - · EPS $-0.06

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 5일 (화) · 장 마감 후 EPS -32.4% 매출 -1.0%

🔔 Earnings release 2026년 2월 23일 (월) · 장 마감 후 EPS +368.5% 매출 +1.1%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-7.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-48.2%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

66.1%

✓ 우수

My positionTop 25%

Low range Average High range

Diagnostics & Research Median 52.1% · Top 22%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-76.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-47.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-73.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.63

✓ Average

My positionMid-range

Low range Average High range

Diagnostics & Research Median 0.38

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

2.40

✓ 양호

My positionMid-range

Low range Average High range

Diagnostics & Research Median 2.23

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

2.19

✓ 양호

My positionMid-range

Low range Average High range

Diagnostics & Research Median 2.15

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$6.14

현재가 대비 +12.9%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

36.00배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

PEG (성장 반영 밸류)

0.55

저평가

💡 PEG < 1 — 성장 대비 저렴

내년 EPS 예상 성장률

+146.7%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+65.4%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

+156.8%

평균 서프라이즈

2026.05.05

하회

실적 $-0.09 · 예상 $-0.07 -34.7%

2026.02.23

상회

실적 $0.04 · 예상 $-0.02 +348.3%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Turnaround Expected

Past performance was weak, but the outlook is positive

Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+2.1%

부진

My positionBottom 25%

Low range Average High range

초고성장주 소형주 Median 51.6% · Bottom 23%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+146.7%

우수

My positionTop 25%

Low range Average High range

초고성장주 소형주 Median 33.7% · Top 16%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+65.4%

우수

My positionTop 25%

Low range Average High range

초고성장주 소형주 Median 40.0% · Top 23%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

-41.7%

부진

My positionBottom 25%

Low range Average High range

초고성장주 소형주 Median 6.9% · Bottom 16%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

-8.0%

평균

My positionMid-range

Low range Average High range

초고성장주 소형주 Median 7.0% · Bottom 32%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+5.2%

부진

My positionBottom 25%

Low range Average High range

초고성장주 소형주 Median 32.4% · Bottom 14%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+2.3%

평균

My positionMid-range

Low range Average High range

초고성장주 소형주 Median 14.5% · Bottom 29%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -151%p below the market

MYGN -82.4% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-150.7%p

Significantly behind the market

vs Health Care (XLV)

-106.9%p

Significantly behind the sector average

1-year basis

vs S&P 500

+6.2%p

slightly ahead of the market

vs Health Care (XLV)

+2.5%p

roughly in line with the sector average

Current position within 52-week range

Low (-54.1%p) High (-36.7%p)

Current price is 54.1% above the 52-week low and 36.7% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-33.2%

Annualized volatility

66.8%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔵

Current diagnosis · 2026-07-27

Oversold zone — rebound potential

Current price $5.44 fell below the lower band ($5.49). Selling pressure excessive; worth watching for a short-term bounce. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD 0.172 · Signal 0.292 · Hist -0.119. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 46.3 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 2.9.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Assets·Vs. Sales, Pricey on Vs. Earnings

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Pricey

🏢 Vs. Assets Cheap

🧾 Vs. Sales Cheap

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

36.00x

✓ Pricey

My positionBottom 25%

Low range Average High range

Diagnostics & Research median 22.77x · Bottom 22% — expensive within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

1.52x

✓ Very cheap

My positionTop 25%

Low range Average High range

Diagnostics & Research median 3.37x · Top 16% — relatively cheap within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

0.62x

✓ Very cheap

My positionTop 5%

Low range Average High range

Diagnostics & Research median 4.06x · Top 1% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$6.14 vs. current price +12.9%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Diagnostics & Research

Who owns it?

Ownership is broadly stable

Insider modest net buying +2.1% · Institutional net selling -6.2% · Short interest moderate 9.1% · Short interest fell -4.0%p over the last 90 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

+2.1%

Insiders net buying

🏦 Institutions (funds & investors)

-6.2%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 92.3%

Institution-led, stable structure

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 7.0%

Meaningful insider stake

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 0.7%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

9.1%

Moderate

Healthcare 소형주 Median 11.2%

Past 90 days 📉 -4.0%p decrease

Short interest days to cover

5.0 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 94.4M주

Float (tradable shares) 87.9M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding MYGN

ETFs with the highest weightings · 10 total shown

FSCC

Federated Hermes MDT Small Cap Core ETF

0.45%

$307M

GNOM

Global X Genomics & Biotechnology ETF

0.35%

$79M

QQQS

Invesco NASDAQ Future Gen 200 ETF

0.28%

$21M

HAPS

Harbor Human Capital Factor US Small Cap ETF

0.27%

$170M

PSCH

Invesco S&P SmallCap Health Care ETF

0.26%

$162M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
MYGN This Stock	$513.8M	-	1.5 ▲	-76.73% ▼	-	-3.0%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 미리어드 제네틱스(MYGN)?

미리어드 제네틱스(MYGN) belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is the market cap of MYGN?

The market cap of MYGN is approximately $514M, ranking 3,181 within its sector.

What is the 52-week high and low for MYGN?

MYGN has recorded a 52-week high of $8.59 and a low of $3.53.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.